Astellas, Seeking Sales in India, Opens Mumbai Office (India)
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma Inc. recently opened the doors of an office in Mumbai, India. The new facility offers Astellas a major opportunity to access the fast growing Indian pharmaceutical market. Currently, the country's drug market is valued at $6.2 billion, making it the number four market in Asia. According to projections by McKinsey & Co. that figure will soar 12 percent every year to $20 billion in 2015. The Asian market outside of Japan presently makes up only 3 percent of Astellas' revenue, a fact the company plans to change in the face of tightening drug pricing restrictions in Japan. (Click here for more - May Require Free Registration
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.